Clinical Trial Update: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of RC88 in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• RC88

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Primary Peritoneal Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED